Related Experiment Videos
Myeloperoxidase-deficient polymorphonuclear leucocytes. (IV): Relation to FAB-classification in acute myeloid
Abstract:
In 148 consecutive cases of untreated acute myeloid leukaemia (AML) the relation between an increased number of myeloperoxidase (MPO)-deficient polymorphonuclear leucocytes (PMN) and a classification modified after the proposals outlined by the French-American-British Co-operative Group, the FAB classification, was investigated. In 22 cases with minimal granulocytic component, 8 M5, 13 M6, 1 M7, no one (0%) showed an increased number of MPO-deficient PMN. In 3 (13%) of 23 cases with slight granulocytic component, 3 M0, 20 M1, and in 49 (57%) of 86 cases with granulocytic differentiation (53 M2, 1 M3, 32 M4), an increased number was demonstrated. This difference was statistically significant at a high level (P less than 0.0001). The number of MPO-deficient PMN could not be estimated in 15 cases of AML and 2 additional cases were mixed leukaemias. It is concluded that an increased number of MPO-deficient PMN in acute leukaemia speaks in favour not only of AML, but suggests the diagnosis of subtypes with some granulocytic component, most likely M1, M2, M3 or M4. Furthermore, the results support the concept that in AML at least some of the mature myeloid cells may be involved in the leukaemic process.
Insights
An increased number of myeloperoxidase (MPO)-deficient polymorphonuclear leucocytes (PMN) is linked to specific subtypes of acute myeloid leukaemia (AML). This finding aids in diagnosing AML and understanding its cellular involvement.
Area of Science:
- Hematology
- Oncology
- Cell Biology
Background:
- Acute myeloid leukaemia (AML) is a heterogeneous group of blood cancers.
- Myeloperoxidase (MPO) deficiency in polymorphonuclear leucocytes (PMN) is a known phenomenon.
- The French-American-British (FAB) classification is a standard for AML subtyping.
Purpose of the Study:
- To investigate the correlation between increased MPO-deficient PMN and AML subtypes.
- To determine if MPO-deficient PMN can aid in AML diagnosis and classification.
Main Methods:
- Analysis of 148 consecutive untreated AML cases.
- Classification of AML cases according to the FAB criteria.
- Quantification of MPO-deficient PMN in peripheral blood leukocytes.
Main Results:
- No MPO-deficient PMN increase was observed in AML subtypes with minimal granulocytic component (M5, M6, M7).
- Increased MPO-deficient PMN were found in 13% of cases with slight granulocytic component (M0, M1) and 57% with granulocytic differentiation (M2, M3, M4).
- The observed differences were statistically significant (P < 0.0001).
Conclusions:
- An elevated count of MPO-deficient PMN suggests AML, particularly subtypes with granulocytic components (M1-M4).
- This finding supports the involvement of mature myeloid cells in the leukemic process of AML.
- MPO-deficient PMN may serve as a diagnostic marker for specific AML subtypes.